63 related articles for article (PubMed ID: 15272600)
1. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
[TBL] [Abstract][Full Text] [Related]
2. Tumor markers in clinical practice: a review focusing on common solid cancers.
Duffy MJ
Med Princ Pract; 2013; 22(1):4-11. PubMed ID: 22584792
[TBL] [Abstract][Full Text] [Related]
3. Tumour Marker Requisition Pattern in a Tertiary Care Centre of Eastern Nepal.
Niraula A; Gelal B; Chaudhari RK; Das BK; Lamsal M
Kathmandu Univ Med J (KUMJ); 2022; 20(80):422-426. PubMed ID: 37795716
[TBL] [Abstract][Full Text] [Related]
4. Relevance of blood tumor markers in inpatients with significant involuntary weight loss and elevated levels of inflammation biomarkers.
Gronnier M; Hedhli K; Sauzay C; Salle V; Duhaut P; Schmidt J; Dernoncourt A
BMC Cancer; 2024 Apr; 24(1):468. PubMed ID: 38622530
[TBL] [Abstract][Full Text] [Related]
5. External quality assessment of tumour marker analysis: state of the art and consequences for estimating diagnostic sensitivity and specificity.
Reinauer H; Wood WG
Ger Med Sci; 2005 May; 3():Doc02. PubMed ID: 19675719
[TBL] [Abstract][Full Text] [Related]
6. [Use of tumor markers in patients on chronic hemodialysis].
Kuno T; Kaizu K
Nihon Rinsho; 2004 Jun; 62 Suppl 6():391-4. PubMed ID: 15250332
[No Abstract] [Full Text] [Related]
7. [Biomarkers for neoplasmas in digestive organs].
Iwasaki Y; Arai K; Katayanagi S; Takahashi K; Yamaguchi T; Matsumoto H; Miyamoto H
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1015-20. PubMed ID: 15272578
[TBL] [Abstract][Full Text] [Related]
8. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
9. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A
Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540
[TBL] [Abstract][Full Text] [Related]
10. Tumor markers in patients with chronic renal failure.
Filella X; Cases A; Molina R; Jo J; Bedini JL; Revert L; Ballesta AM
Int J Biol Markers; 1990; 5(2):85-8. PubMed ID: 1704405
[TBL] [Abstract][Full Text] [Related]
11. Carbohydrate antigens as potential biomarkers for the malignancy in patients with idiopathic deep venous thrombosis: a retrospective cohort study.
Yu M; Wang YH; Abdalla AME; Liu WQ; Mei F; Wang J; Ouyang CX; Li YQ
J Huazhong Univ Sci Technolog Med Sci; 2014 Oct; 34(5):722-728. PubMed ID: 25318883
[TBL] [Abstract][Full Text] [Related]
12. [Clinical usefulness of circulating tumor markers].
Ohkura H
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1131-4. PubMed ID: 15272600
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]